在出血控制试验中平衡入组与死亡率:PROPPR试验的二次分析
该研究为PROPPR试验的二次分析,按到达急诊科后30分钟随机化时间间隔比较患者结局。随机化在30分钟内的患者损伤严重度更高(中位ISS 29 vs 26,p<0.01)、收缩压更低(中位91 vs 102 mmHg,p<0.01)、穿透伤比例更高(50% vs 47%,p<0.01)。随机化时间越快,24小时死亡率(0-30分钟20%,31-60分钟9%,61-90分钟10%,91-120分钟0%,p<0.01)和30天死亡率(p<0.01)越高。随机化时间与不良事件、手术干预或止血时间无显著关联。作者建议未来出血控制试验设计者考虑缩短随机化时间以平衡入组与死亡率。
要点
- 随机化在到达后0-30分钟的患者24小时死亡率为20%,31-60分钟为9%,61-90分钟为10%,91-120分钟为0%(p<0.01)。
- 0-30分钟随机化组损伤更重:中位ISS 29 vs 26(p<0.01),中位收缩压91 vs 102 mmHg(p<0.01),穿透伤50% vs 47%(p<0.01)。
- 随机化时间与30天死亡率相关(p<0.01),但与不良事件、手术干预或止血时间无显著关联。
- 仅57%患者在0-30分钟窗口入组,仅3%在91-120分钟窗口入组,后者24小时内无死亡。
- 作者认为未来出血控制试验应缩短随机化时间以更好平衡入组与死亡率。
适用人群与场景
- PROPPR试验纳入的到达急诊科2小时内、有大量输血风险的受伤患者。
研究设计与关键结果
- 研究类型:PROPPR试验的二次分析,多中心随机试验。
- 按到达急诊科后30分钟随机化时间间隔分组比较。
- 0-30分钟随机化组中位ISS 29 vs 26(p<0.01),中位收缩压91 vs 102 mmHg(p<0.01),穿透伤50% vs 47%(p<0.01)。
- 24小时死亡率:0-30分钟20%,31-60分钟9%,61-90分钟10%,91-120分钟0%(p<0.01)。
- 30天死亡率随随机化时间延长而降低(p<0.01)。
- 随机化时间与不良事件、手术干预或止血时间无显著关联。
- 仅57%患者在0-30分钟窗口入组,仅3%在91-120分钟窗口入组,后者24小时内无死亡。
证据类型、等级与局限
- 证据类型:多中心随机试验的二次分析;证据等级:预后与流行病学,Level II。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,为更好平衡入组与死亡率,未来出血控制干预试验的设计者应考虑缩短随机化时间。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Designing clinical trials on hemorrhage control requires carefully balancing the need for high enrollment numbers with the need of focusing on the sickest patients. The Pragmatic Randomized Optimal Platelet and Plasma Ratios (PROPPR) trial enrolled patients within 2 hours of arrival to the emergency department for a trial of injured patients at risk for massive transfusion. We conducted a secondary analysis to determine how time-to-randomization affected patient outcomes and the balance between enrollment and mortality.
METHODS: Patients from the Pragmatic Randomized Optimal Platelet and Plasma Ratios trial were compared based on 30-minute time to randomization intervals. Outcomes included 24-hour and 30-day mortality, time to hemostasis, adverse events, and operative procedures. Additional analyses were conducted based on treatment arm allocation, mechanism of injury, and variation in start time (arrival vs. randomization).
RESULTS: Randomization within 30 minutes of arrival was associated with higher injury severity (median Injury Severity Score, 29 vs. 26 overall; p < 0.01), lower systolic blood pressure (median, 91 vs. 102 mm Hg overall; p < 0.01), and increased penetrating mechanism (50% vs. 47% overall; p < 0.01). Faster time-to-randomization was associated with increased 24-hour (20% for 0- to 30 minute entry, 9% for 31-minute to 60-minute entry, 10% for 61-minute to 90-minute entry, 0% for 91-minute to 120-minute entry; p < 0.01) and 30-day mortality (p < 0.01). There were no significant associations between time-to-randomization and adverse event occurrence, operative interventions, or time to hemostasis.
CONCLUSION: Increasing time to randomization in this large multicenter randomized trial was associated with increased survival. Fastest randomization (within 0-30 minutes) was associated with highest 24-hour and 30-day mortality, but only 57% of patients were enrolled within this timeframe. Only 3% of patients were enrolled within the last 30-minute window (91-120 minutes), with none of them dying within the first 24 hours. For a more optimal balance between enrollment and mortality, investigators should consider shortening the time to randomization when planning future clinical trials of hemorrhage control interventions.
LEVEL OF EVIDENCE: Prognostic and Epidemiologic; Level II.
参考来源
- Abraham PJ, Gonzalez-Sigler I, Reynolds L, et al. Balancing enrollment and mortality in hemorrhage control trials: A secondary analysis of the PROPPR trial. J Trauma Acute Care Surg. 2022. PMID: 35609292. doi:10.1097/TA.0000000000003550
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。